Scientist profiles G-L
Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room G1 57
Research Administrative Assistant: Tilley Creary
Phone: 416-480-4055 ext. 7834
Dr. Juurlink is a staff internist and head of the division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto. He is also a medical toxicologist at the Ontario Poison Centre at the Hospital for Sick Children and a scientist at the Institute for Clinical Evaluative Sciences.
He received degrees in Pharmacy (1990) and Medicine (1994) from Dalhousie University in Halifax, Nova Scotia, and completed postgraduate training in Internal Medicine (1998) followed by residency in Clinical Pharmacology (2000), a fellowship in Medical Toxicology (2002), and a PhD in Clinical Epidemiology (2003), all at the University of Toronto. He has received certification from the American Board of Internal Medicine, the American Board of Emergency Medicine (Medical Toxicology), and the American Board of Clinical Pharmacology.
He is presently the Sunnybrook site director for the program in Clinical Pharmacology & Toxicology and is actively involved with the Royal College of Physicians and Surgeons subspecialty program in Clinical Pharmacology and Toxicology as a member of the Nucleus committee and Vice Chair of the Examinations committee.
In addition to his clinical, teaching, and administrative activities, Dr. Juurlink maintains an active research program in the field of drug safety. His areas of particular interest include drug safety, adverse drug events, the consequences of drug-drug interactions in clinical practice, and the epidemiology of suicide and deliberate self-poisoning.
- B.Phm., 1990, pharmacy, Dalhousie University, Canada
- MD, 1994, Dalhousie University, Canada
- FRCPC, 1998, internal medicine, University of Toronto, Canada
- FRCPC, 2000, clinical pharmacology, U of T, Canada
- Fellowship, 2002, medical toxicology, U of T, Canada
- PhD, 2003, clinical epidemiology, U of T, Canada
Appointments and Affiliations:
- Scientist, Evaluative Clinical Sciences, Schulich Heart Research Program, Sunnybrook Research Institute
- Senior scientist, Institute for Clinical Evaluative Sciences
- Professor, departments of medicine and pediatrics, U of T
- Staff physician, divisions of general internal medicine and clinical pharmacology, Sunnybrook Health Sciences Centre
- Medical toxicologist, Ontario Poison Information Centre, Hospital for Sick Children
- Drug safety
- Epidemiology of adverse drug events
Well-intended prescribing by physicians can often have unintended consequences for patients. This is sometimes because the patients in real-world clinical practice are less healthy (or less closely monitored) than those enrolled in the premarketing studies used to characterize drug safety and effectiveness. However, some drug-related side effects are sufficiently uncommon that they only become apparent after a drug has enjoyed widespread use by large numbers of patients.
Dr. Juurlink’s research explores the epidemiology of adverse drug events using anonymized population-based health care data to explore the complex interrelationships between drug therapy and harm. One of his primary interests is the clinical consequences of drug-drug interactions, which typify avoidable drug-related injury. As a medical toxicologist, he also studies the epidemiology of deliberate self-harm, including drug overdose and suicide.
Related News and Stories:
- Is there still a place for opioids? Doctors are grappling with how to relieve acute pain while minimizing opioid use and averting descent into chronic pain (from 2016 SRI Magazine)
- When drugs collide: Medications taken in combination can be toxic, sometimes fatally—but how to know which ones, and in what combination? (SRI Magazine, 2010)
- New network to improve drug studies: Cross-country research network pairs with Health Canada to improve drug safety and efficacy studies (March 3, 2009)
- Important announcement for patients taking common cardiac drugs: Canadian Medical Association Journal releases study about heart attack risk and drug combinations (January 28, 2009)